- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust imm...
-Sail Biomedicines, Inc. (“Sail” or the “Company”), a Flagship Pioneering company and leader in RNA-based programmable medicines, a...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...
The two companies will collaboratively conduct early-stage research for these two programs. Elpiscience will also grant Astellas the right to add up to two...
Set-up of first BioNTainer as high-tech manufacturing solution for mRNA medicines is a critical step in establishing a resilient vaccine ecosystem in Afr...
The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: NCT06082050). This trial's primary objectives are to ...
Parse Biosciences, a leading provider of easily accessible and scalable solutions for single-cell sequencing, announced today that the company has raised $...
OmniAb, Inc. announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken...
Macrogen Europe is seeking to expand within Switzerland from its foothold in Basel with its Sanger sequencing laborato...
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously challenging and aggressive form of cancer, usually diagnosed in advanced stages, making curative t...
In 2016, IMIDomics entered into a strategic partnership with BMS to harness their unique clinical and molecular database, and multidimensional analysis con...
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium ...
For almost a decade, Momentum has been offering clients a wide range of early drug discovery services including high-throughput screening, hit characteriza...
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...
© 2024 Biopharma Boardroom. All Rights Reserved.
